Bing

SEARCH HISTORY

See what other ETFs contain UTHR » See what other stocks are held by FBT » UTHR operates in the Biotechnology sector, among companies like Emergent BioSolutions Inc (NYSE: EBS) which is off about 1.8% today, and Isis Pharmaceuticals, Inc.
Forbes · 12/7/2011
Analyst Raj Mehra of Auriga USA maintains his "buy" rating on United Therapeutics (NASDAQ: UTHR), while raising his estimates for the company. The target price for UTHR has been raised from $54 to $70. According to Auriga USA, United …
Benzinga · ByMonica Gerson · 1/13/2010
Within this sub-industry, one stock that has been a strong performer this Fall is United Therapeutics Corp (UTHR). Ever since August 29th when a US District Court judge made a favorable ruling on patents over the Remodulin drug, UTHR has been on fire.
Stockhouse · 10/21/2014
The year-to-date return of United Therapeutics Corporation (NASDAQ:UTHR)’s stock is almost 34% ... This is a FREE report from Insider Monkey. Credit Card is NOT required.
INSIDER MONKEY · 8/15/2013
What: Shares of United Therapeutics (NASDAQ: UTHR ) , a biopharmaceutical company that develops ... make up for the eventual loss of exclusivity on Remodulin, then chasing the stock higher after today may not be the best idea. United Therapeutics may ...
The Motley Fool · BySean Williams · 8/30/2014
Active traders and day traders have many stocks to choose from this Monday morning. We are tracking news and moves in shares of BioSante Pharmaceuticals (NASDAQ: BPAX), unOpta, Inc. (NASDAQ: STKL), and United Therapeutics Corporation …
24/7 Wall ST · 6/6/2011
UTHR stock price is reasonably priced at 18.5 times current EPS, but the company reported two quarterly deficits during the past two years. The deficits were caused by extensive share-based compensation to executives and employees. Earnings are …
Cabot Investing Advice · 3/23/2015
Releasing their earnings report Tuesday, United Therapeutics Corporation (UTHR) closed Tuesday at $155.16 ... Earnings, adjusted for stock option expense and non-recurring costs, were $3.21 per share. The results topped Wall Street expectations.
wallstreetscope.com · 2/25/2015
UTHR) and TNI BioTech, Inc (OTCMKTS: TNIB): Are Concerns About Drug Prices Overblown? Credit Suisse analyst Ravi Mehrotra believes a rally in large-cap biotech stocks can be resurrected in part because concerns about drug prices might be overblown ...
Smallcap Network · ByJohn Udovich · 5/16/2014
United Therapeutics Inc. (UTHR) stock rallied 28.5% yesterday on news that the biopharmaceutical company has received a favorable court ruling in a patent fight with Novartis AG (NVS). In 2011, Sandoz International, Novartis’ subsidiary, announced plans ...
bidnessetc.com · 8/30/2014